T1	Participants 429 503	evaluated 132 patients with hematological malignancy in complete remission
T2	Participants 673 693	who received G-CSF a
T3	Participants 1525 1603	4.21%, and showed a higher tendency in the G-CSF group (p < 0.100, chi2 test).
